Skip to main content

Methamphetamine Disease Interactions

There are 8 disease interactions with methamphetamine.

Major

CNS stimulants (applies to methamphetamine) cardiac disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Heart Disease, Hypertension, Pheochromocytoma, Hyperthyroidism, Peripheral Arterial Disease

Many CNS stimulants are contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc. Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who are treated with CNS stimulants at the recommended dosages for attention deficit hyperactivity disorder; use of these agents should be avoided in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease. Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias, and other symptoms have been reported in adults under treatment. A careful assessment of the cardiovascular status should be done in patients being considered for treatment. This includes family history, physical exam, and further cardiac evaluation (EKG and echocardiogram). Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.

References

  1. (2001) "Product Information. Provigil (modafinil)." Cephalon, Inc
  2. (2001) "Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation
  3. (2001) "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham
  4. (2001) "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn
  5. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  6. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  7. (2002) "Product Information. Concerta (methylphenidate)." Alza
  8. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company
  9. (2007) "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc
  10. (2007) "Product Information. Nuvigil (armodafinil)." Cephalon Inc
  11. (2012) "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc
  12. (2019) "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc
  13. (2023) "Product Information. Desoxyn (methamphetamine)." Recordati Rare Diseases Inc, SUPPL-38
View all 13 references
Major

CNS stimulants (applies to methamphetamine) hypertension

Major Potential Hazard, Moderate plausibility.

CNS stimulants increase blood pressure and heart rate; the use of some agents may be contraindicated in patients with severe/uncontrolled hypertension. Caution should be used when administering to patients with preexisting high blood pressure (even mild hypertension) and other cardiovascular conditions. All patients under treatment should be regularly monitored for potential tachycardia and hypertension.

References

  1. (2001) "Product Information. Provigil (modafinil)." Cephalon, Inc
  2. (2001) "Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation
  3. (2001) "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham
  4. (2001) "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn
  5. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  6. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  7. (2002) "Product Information. Concerta (methylphenidate)." Alza
  8. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company
  9. (2007) "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc
  10. (2007) "Product Information. Nuvigil (armodafinil)." Cephalon Inc
  11. (2012) "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc
  12. (2019) "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc
  13. (2023) "Product Information. Desoxyn (methamphetamine)." Recordati Rare Diseases Inc, SUPPL-38
View all 13 references
Major

CNS stimulants (applies to methamphetamine) psychiatric disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis, Depression

The use of CNS stimulants can cause psychotic symptoms, suicidal ideation, and aggression, and can exacerbate symptoms of behavior disturbance and thought disorder; CNS stimulants may induce a manic or mixed episode in patients with bipolar disorder. Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders. All patients (particularly those with psychotic or bipolar disorders) should be monitored closely, especially during treatment initiation and at times of dose changes. Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder. Prior to initiating therapy, all patients should be screened for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or family history of suicide, bipolar disease, or depression). If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered. Some CNS stimulants are contraindicated in patients with marked agitation or anxiety.

References

  1. (2001) "Product Information. Provigil (modafinil)." Cephalon, Inc
  2. (2001) "Product Information. Cylert (pemoline)." Abbott Pharmaceutical
  3. (2001) "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals
  4. (2001) "Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation
  5. (2001) "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham
  6. (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
  7. (2001) "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn
  8. (2001) "Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim
  9. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  10. (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
  11. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  12. (2002) "Product Information. Concerta (methylphenidate)." Alza
  13. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company
  14. (2007) "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc
  15. (2007) "Product Information. Nuvigil (armodafinil)." Cephalon Inc
  16. (2012) "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc
  17. (2020) "Product Information. Fintepla (fenfluramine)." Zogenix, Inc
  18. (2023) "Product Information. Qsymia (phentermine-topiramate)." Vivus Inc, SUPPL-23
  19. (2019) "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc
  20. (2023) "Product Information. Desoxyn (methamphetamine)." Recordati Rare Diseases Inc, SUPPL-38
View all 20 references
Major

CNS stimulants (applies to methamphetamine) substance abuse

Major Potential Hazard, Moderate plausibility. Applicable conditions: Alcoholism, Drug Abuse/Dependence

CNS stimulants (especially amphetamines) have a high potential for abuse and misuse, which can lead to development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants can result in overdose and death; this risk is increased with higher doses or unapproved methods of administration (e.g., snorting, injection). Before prescribing a CNS stimulant, each patient's risk for abuse, misuse, and addiction should be assessed. Throughout therapy, it is recommended to reassess each patient's risk and frequently monitor for signs/symptoms of abuse, misuse, and addiction. Therapy with CNS stimulants should be administered cautiously, if at all, in patients with a history of alcohol or substance abuse. The use of some agents is contraindicated in patients with a history of drug abuse.

References

  1. (2001) "Product Information. Cylert (pemoline)." Abbott Pharmaceutical
  2. (2001) "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals
  3. (2001) "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham
  4. (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
  5. (2001) "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn
  6. (2001) "Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim
  7. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  8. (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
  9. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  10. (2007) "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc
  11. (2019) "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc
  12. (2023) "Product Information. Desoxyn (methamphetamine)." Recordati Rare Diseases Inc, SUPPL-38
View all 12 references
Major

CNS stimulants (applies to methamphetamine) tics

Major Potential Hazard, Moderate plausibility. Applicable conditions: Tic Disorder

CNS stimulants have been reported to worsen Tourette's syndrome and exacerbate motor and verbal tics. Before initiating therapy, it is recommended to assess family history and clinically evaluate patients for tics or Tourette's syndrome. Therapy with CNS stimulants, if necessary, should be administered cautiously in patients with tic disorders or family history of Tourette's syndrome. The manufacturers of the CNS stimulants, methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer), consider their use to be contraindicated in such patients.

References

  1. (2001) "Product Information. Cylert (pemoline)." Abbott Pharmaceutical
  2. (2001) "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals
  3. (2001) "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham
  4. (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
  5. (2001) "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn
  6. (2001) "Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim
  7. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  8. (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
  9. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  10. (2007) "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc
  11. (2023) "Product Information. Desoxyn (methamphetamine)." Recordati Rare Diseases Inc, SUPPL-38
View all 11 references
Moderate

CNS stimulants (applies to methamphetamine) liver disease

Moderate Potential Hazard, Moderate plausibility.

In general, CNS stimulants are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly in certain agents. Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury; laboratory testing should be done at the first sign/symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.

References

  1. (2001) "Product Information. Provigil (modafinil)." Cephalon, Inc
  2. (2001) "Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation
  3. (2001) "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham
  4. (2001) "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn
  5. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  6. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  7. (2002) "Product Information. Concerta (methylphenidate)." Alza
  8. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company
  9. (2007) "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc
  10. (2007) "Product Information. Nuvigil (armodafinil)." Cephalon Inc
  11. (2012) "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc
  12. (2023) "Product Information. Desoxyn (methamphetamine)." Recordati Rare Diseases Inc, SUPPL-38
View all 12 references
Moderate

CNS stimulants (applies to methamphetamine) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response. The dosage should be adjusted accordingly in certain agents.

References

  1. (2001) "Product Information. Provigil (modafinil)." Cephalon, Inc
  2. (2001) "Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation
  3. (2001) "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn
  4. (2007) "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc
  5. (2019) "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc
  6. (2023) "Product Information. Desoxyn (methamphetamine)." Recordati Rare Diseases Inc, SUPPL-38
View all 6 references
Moderate

CNS stimulants (applies to methamphetamine) seizure disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Seizures

Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures. These drugs may lower the convulsive threshold in patients with history of seizures, with prior electroencephalogram (EEG) abnormalities without seizures, and very rarely, without history of seizures and no prior EEG evidence of seizures. Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures. If seizures occur, therapy should be discontinued.

References

  1. (2001) "Product Information. Provigil (modafinil)." Cephalon, Inc
  2. (2001) "Product Information. Cylert (pemoline)." Abbott Pharmaceutical
  3. (2001) "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham
  4. (2001) "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn
  5. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  6. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  7. (2002) "Product Information. Concerta (methylphenidate)." Alza
  8. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company
  9. (2007) "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc
  10. (2007) "Product Information. Nuvigil (armodafinil)." Cephalon Inc
  11. (2012) "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc
  12. (2023) "Product Information. Desoxyn (methamphetamine)." Recordati Rare Diseases Inc, SUPPL-38
View all 12 references

Methamphetamine drug interactions

There are 233 drug interactions with methamphetamine.

Methamphetamine alcohol/food interactions

There are 3 alcohol/food interactions with methamphetamine.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.